Zydus Cadila gets emergency nod to market anti-arrhythmic drug for treating moderate Covid-19

Drug firm Zydus Cadila on Friday said it has received final approval from the US health regulator to market anti-arrhythmic drug Propafenone Hydrochloride extended release tablets. Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat. Here is what Dr Sharvil Patel of Zydus Group have to say.